Enhanced design offers improved ergonomics and procedural efficiency for a device that targets three points of resistance in the conventional outflow pathway.
Expands the firm's pharmaceutical and device research, development, and clinical capabilities that enhance the ability to provide hybrid ophthalmic therapies.
iStent inject achieved 42 percent reduction in Mean IOP to 14.6 mmHg and 82 percent reduction in mean medications to 0.55 at three years postoperative.